[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Combined Military Hospital, Pakistan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652809","phase-2-topical-metformin-versus-triple-regimen-for-epidermal-melasma-100652809",false,"NCT07779811","Topical Metformin Versus Triple Regimen for Epidermal Melasma","Comparison of Efficacy of Topical Triple Regimen Versus 30% Metformin in the Treatment of Epidermal Melasma","MET-MEL","Inclusion Criteria:\n\n* Male or female participants aged 18 to 50 years.\n* Confirmed diagnosis of epidermal melasma according to the study's operational definition.\n* Epidermal melasma confirmed by Wood's lamp examination, showing accentuated hyperpigmentation with enhanced contrast and sharp borders.\n* No treatment for epidermal melasma during the previous one month.\n* No dermabrasion, laser ablation, or chemical peel during the previous three months.\n* Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Acne vulgaris.\n* Rosacea.\n* Pregnancy.\n* Presence of comorbid conditions.","ALL","18 Years","50 Years",{"count":21,"type":22},104,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Melasma is a common skin condition that causes dark brown patches, mainly on sun-exposed areas of the face. It is often persistent, may recur after treatment, and can affect a person's quality of life. The standard topical triple regimen used for melasma contains hydroquinone, tretinoin, and fluocinolone acetonide. Although effective, prolonged use may cause adverse effects such as redness, burning, peeling, telangiectasia, and steroid-related skin changes. Topical metformin has recently been investigated as a possible alternative treatment because it may reduce skin pigmentation with relatively few side effects.\n\nThis randomized clinical trial will compare the efficacy of topical 30% metformin cream with a topical triple regimen in adults with epidermal melasma. A total of 104 participants aged 18-50 years will be enrolled, with 52 participants assigned to each treatment group. Group A will receive topical 30% metformin, while Group B will receive a triple regimen containing 2% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide. Participants will apply the assigned treatment once daily at night for eight consecutive weeks. All participants will also be advised to use SPF 50 or higher sunscreen in the morning.\n\nTreatment efficacy will be assessed by comparing the modified Melasma Area and Severity Index score at baseline and after eight weeks. Treatment will be considered effective when the participant achieves at least a 25% reduction in the modified MASI score from baseline. The findings may help identify a more effective and acceptable topical treatment option for patients with epidermal melasma",[28,29],"Epidermal Melasma","Facial Hyperpigmentation",[31,28,29,32,33,34,35,36],"Melasma","Topical Metformin","Triple Combination Therapy","Modified MASI","Randomized Clinical Trial","Topical Treatment","NOT_YET_RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":22},"2026-08-15",{"date":45,"type":22},"2027-01-30",{"name":47,"class":48},"Combined Military Hospital, Pakistan","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100633339","comparative-evaluation-of-oral-ursodeoxycholic-acid-in-reducing-bilirubin-levels-among-patients-with-acute-viral-hepatitis-100633339","NCT07525401","Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis","AVH","Inclusion Criteria:\n\n* All patients of either gender\n* aged \\>18 years to 50 years with acute viral hepatitis are included\n\nExclusion Criteria:\n\n* Patients having Hepatitis B, C\n* hepatocellular carcinoma\n* primary biliary cholangitis\n* choldocholithiasis\n* patients having normal bilirubin levels with AVH were excluded.",{"count":58,"type":22},88,[60],"NA","Hepatitis is an inflammatory condition of the liver that has emerged as a significant global health concern due to its widespread prevalence.\n\nData on ursodeoxycholic acid in acute viral hepatitis remain limited. Some studies suggest its positive effect in cholestatic phase of viral hepatitis. UDCA may reduce cholestatic symptoms like jaundice and pruritus potentially shortening hospital stay and improving patient outcomes. However, robust clinical data supporting its routine use in acute viral hepatitis are lacking, and current treatment remains largely supportive. Given the high burden of acute viral hepatitis in our region and the potential for UDCA to improve cholestatic phase of AVH there is a clear need for well-designed clinical studies evaluating its therapeutic role. This study aims to evaluate the role of oral ursodeoxycholic acid in biochemical recovery of patients with acute viral hepatitis. If positive role is confirmed, it will be incorporated in standard treatment and if no role is found unnecessary use will be discouraged.\n\nNull Hypothesis (H₀):\n\nOral ursodeoxycholic acid has no significant effect on the bilirubin levels of patients with acute viral hepatitis.\n\nH₀: There is no statistically significant difference in bilirubin levels between patients receiving ursodeoxycholic acid and those receiving supportive care alone.\n\nAlternative Hypothesis (H₁):\n\nOral ursodeoxycholic acid reduces bilirubin levels in patients with acute viral hepatitis. H₁: There is statistically significant difference in bilirubin levels between patients receiving ursodeoxycholic acid and those receiving supportive care alone.",[63,64],"Hepatitis A","Hepatitis E Virus Infection",[66,67,68,63,69],"Acute viral hepatitis","Ursodeoxycholic acid","UDCA","Hepatitis E","2026-04-10",{"date":72,"type":41},"2026-04-13",{"date":74,"type":22},"2026-04",{"date":76,"type":22},"2026-10",{"name":47,"class":48},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":49},"100536614","phase-3-comparative-efficacy-of-hypertonic-saline-vs-adrenaline-nebulization-in-acute-bronchiolitis-100536614","NCT06267118","Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis","A Randomized Controlled Trial on the Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis in Children","children","Inclusion Criteria:\n\n* All children admitted in PICU with acute bronchiolitis\n\nExclusion Criteria:\n\n* children with co-exiting illnesses like\n\n  1. Congenital Heart Disease\n  2. Immunodeficiency\n  3. other Infectious disease like Meningitis, encephalitis, Pneumonia, TORCH\n  4. Kidneys or liver problem\n  5. Seizures","1 Month","2 Years",{"count":89,"type":22},60,[91],"PHASE3","The goal of this clinical trial is to compare the efficacy of hypertonic saline nebulization with adrenaline nebulization in the treatment of acute bronchiolitis in children. Main aim is to evaluate the following in both group of patients\n\n1. Improvement in Wood-Downes clinical score (WDF score) in bronchiolitis\n2. Length of Hospitalization",[94],"Acute Bronchiolitis Due to Respiratory Syncytial Virus",[96],"Wood-Downes Clinical scoring System","RECRUITING","2024-08-21",{"date":100,"type":41},"2024-08-22",{"date":102,"type":41},"2023-11-01",{"date":104,"type":22},"2024-12-31",{"name":47,"class":48},""]